Endothelium-derived nitric oxide (NO) is a critical mediator of diverse functions in the cardiovascular system. During the tenure of this grant, we have developed the concept that eNOS inactivation/activation can be regulated by its subcellular targeting, multi-site phosphorylation events and locale specific protein-protein interactions with several proteins including caveolin-1 (Cav-1). In exciting preliminary experiments, we have further dissected the interaction between eNOS and Cav-1 and have dissociated the binding of Cav-1 to eNOS from its inhibitory function using mutagenesis of the caveolin scaffolding domain (CSD) and have developed a novel cell permeable, eNOS activator peptide and a mutant form of Cav-1 (F92A Cav-1) that promote NO release. Indeed, a cell permeable peptide of the CSD lacking the key amino acids necessary for eNOS inhibition (called AP-Cav 3PM) prevents the binding of eNOS to Cav-1, but does not inhibit eNOS function compared to the native CSD. AP-Cav 3PM promotes NO release from cells and dose dependently lowers blood pressure in vivo. In additional data supporting the importance of the eNOS/Cav-1 interaction in vivo, we have shown that Cav-1 KO mice bred to atherosclerosis prone ApoE KO mice have a markedly enhanced proatherogenic lipid profile compared to ApoE KO mice alone, but are paradoxically protected from atherogenesis, perhaps due to elevated eNOS activation. Interestingly, breeding ApoE/ Cav-1 KO double KO (dKO) mice to EC specific Cav-1 transgenic mice (Cav-1 RC) to reconstitute Cav-1 and caveolae in the endothelium (ApoE Cav-1 RC), reduces the hyperlipidemia and promotes atherosclerosis. With this background in mind, we hypothesize that understanding the interactions between eNOS and Cav-1 will permit molecular dissection of the physiological (blood flow) and pathophysiological (atherogenesis) roles of Cav-1 as a negative regulator of eNOS and perhaps other proteins. As a corollary to this hypothesis, we predict that a mutant of Cav-1 that does not inhibit eNOS or a cell permeable eNOS activator will antagonize the inhibitory role of Cav-1 on eNOS and promote NO release and improve endothelial cell health, blood flow and reduce atherogenesis. To examine the regulation of this important interaction in more detail, the following Specific Aims are proposed: 1.Define the mechanisms by which the Cav 3PM peptide activates NO release and eNOS function in vivo. 2. Reconstitute F92A Cav -1 into wild-type and Cav-1 KO endothelial cells and vessels and generate transgenic mice that inducibly express F92A Cav-1 in the endothelium and 3. Explore the mechanistic basis of how the genetic reconstitution of Cav-1 in the endothelium of ApoE Cav-1 KO restores atherogenesis. Collectively, this work will facilitate our understanding of the molecular machinery required for eNOS regulation in EC. This research is relevant to public health since endothelial dysfunction is a common manifestation of most cardiovascular diseases. Our research has discovered the major mechanisms of how the endothelium control blood flow and atherogenesis. Research supported by this grant may help identify new drugs that reduce heart disease and improve the quality of life of people suffering with cardiovascular disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37HL061371-14
Application #
8234963
Study Section
Atherosclerosis and Inflammation of the Cardiovascular System Study Section (AICS)
Program Officer
Charette, Marc F
Project Start
1998-12-01
Project End
2014-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
14
Fiscal Year
2012
Total Cost
$450,286
Indirect Cost
$178,210
Name
Yale University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Park, Eon Joo; Grabi?ska, Kariona A; Guan, Ziqiang et al. (2014) Mutation of Nogo-B receptor, a subunit of cis-prenyltransferase, causes a congenital disorder of glycosylation. Cell Metab 20:448-57
Goodwin, Julie E; Feng, Yan; Velazquez, Heino et al. (2014) Loss of the endothelial glucocorticoid receptor prevents the therapeutic protection afforded by dexamethasone after LPS. PLoS One 9:e108126
Goodwin, Julie E; Feng, Yan; Velazquez, Heino et al. (2013) Endothelial glucocorticoid receptor is required for protection against sepsis. Proc Natl Acad Sci U S A 110:306-11
Siragusa, Mauro; Sessa, William C (2013) Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival. Arterioscler Thromb Vasc Biol 33:1852-60
Zhang, Pei; Huang, Bihui; Xu, Xiangru et al. (2013) Ten-eleven translocation (Tet) and thymine DNA glycosylase (TDG), components of the demethylation pathway, are direct targets of miRNA-29a. Biochem Biophys Res Commun 437:368-73
Zhang, Pei; Huang, Angela; Ferruzzi, Jacopo et al. (2012) Inhibition of microRNA-29 enhances elastin levels in cells haploinsufficient for elastin and in bioengineered vessels--brief report. Arterioscler Thromb Vasc Biol 32:756-9
Briand, Nolwenn; Le Lay, Soazig; Sessa, William C et al. (2011) Distinct roles of endothelial and adipocyte caveolin-1 in macrophage infiltration and adipose tissue metabolic activity. Diabetes 60:448-53
Bernatchez, Pascal; Sharma, Arpeeta; Bauer, Philip M et al. (2011) A noninhibitory mutant of the caveolin-1 scaffolding domain enhances eNOS-derived NO synthesis and vasodilation in mice. J Clin Invest 121:3747-55
Davalos, Alberto; Fernandez-Hernando, Carlos; Sowa, Grzegorz et al. (2010) Quantitative proteomics of caveolin-1-regulated proteins: characterization of polymerase i and transcript release factor/CAVIN-1 IN endothelial cells. Mol Cell Proteomics 9:2109-24
Albinsson, Sebastian; Suarez, Yajaira; Skoura, Athanasia et al. (2010) MicroRNAs are necessary for vascular smooth muscle growth, differentiation, and function. Arterioscler Thromb Vasc Biol 30:1118-26

Showing the most recent 10 out of 15 publications